	Application No.	Applicant(s)
Notice of Allowability	10/705 172	CHEN ET AL.
	10/705,173 Examiner	Art Unit
	Charanjit S. Aulakh	1625
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this apply or other appropriate communication (IGHTS). This application is subject to	plication. If not included not will be mailed in due course. THIS
1. This communication is responsive to <u>Paper filed on 15 dec</u>	<u>cember 2006</u> .	
2. The allowed claim(s) is/are 1,2,4-35 and 53.		
3. ☐ Acknowledgment is made of a claim for foreign priority una) ☐ All b) ☐ Some* c) ☐ None of the:  1. ☐ Certified copies of the priority documents have	• .,,,	
2. ☐ Certified copies of the priority documents have		
Copies of the certified copies of the priority do	•••	<del></del>
International Bureau (PCT Rule 17.2(a)).	dunients have been received in this	national stage application from the
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	MENT of this application.	
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give	nitted. Note the attached EXAMINER' es reason(s) why the oath or declara	S AMENDMENT or NOTICE OF tion is deficient.
5. CORRECTED DRAWINGS ( as "replacement sheets") mus	st be submitted.	
(a) I including changes required by the Notice of Draftspers	son's Patent Drawing Review (PTO-	948) attached
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	s Amendment / Comment or in the O	iffice action of
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t	.84(c)) should be written on the drawin he header according to 37 CFR 1.121(c	ngs in the front (not the back) of d).
<ol> <li>DEPOSIT OF and/or INFORMATION about the depo- attached Examiner's comment regarding REQUIREMENT</li> </ol>	sit of BIOLOGICAL MATERIAL n FOR THE DEPOSIT OF BIOLOGICA	nust be submitted. Note the AL MATERIAL.
	·	
	•	
	•	
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5 Notice of Information	mana Anna Pan Pan Pan
<ol> <li>Notice of References Cited (FT0-692)</li> <li>Divide of Draftperson's Patent Drawing Review (PT0-948)</li> </ol>	<ol> <li>5. ☐ Notice of Informal Page 6. ☑ Interview Summary</li> </ol>	· •
	o. 🖂 interview Summary Paper No./Mail Date	
<ol> <li>Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 12/15/06, 6/8/05</li> </ol>	7. 🛛 Examiner's Amendm	nent/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8.   Examiner's Stateme	nt of Reasons for Allowance
<del>-</del>	9. ⊠ Other <i>The drawings</i>	are accepted.
	CHARA	S ALLAKH, PH.D MARY EXAMBER

U.S. Patent and Trademark Office PTOL-37 (Rev. 08-06)

Page 2

Application/Control Number: 10/705,173

Art Unit: 1625

## **DETAILED ACTION**

1. According to paper filed on Dec. 15, 2006, the applicants have canceled claims 3, 41, 44, 45, 47, 51 and 52; amended claims 1, 6, 15, 36, 37 and 46 and furthermore, have added new claim 53.

2. Claims 1, 2, 4-40, 42, 43, 46, 48-50 and 53 are now pending in the application.

## EXAMINER'S AMENDMENT

3. The following amendment is pursuant to a telephone conversation with the applicant's attorney, Mr. Roger C. Rich on March 1, 2007. During discussion for amending claims 1 and 6, the attorney was advised that that deleting hydrate or solvate does not limit the compounds to anhydrous compounds only. The following changes have been made in claims:

Cancel claims 36-40, 42, 43, 46 and 48-50.

In claim 1, page 2, line 1 under formula I, <u>after</u> pharmaceutically acceptable salt, <u>delete</u> ---- , hydrate, or solvate -----.

In claim 6, page 4, line 1 under formula II, <u>after</u> pharmaceutically acceptable salt, <u>delete</u> ----- , hydrate, or solvate ------.

In claim 34, lines 1- 2, <u>after</u> selected from, <u>delete</u> --- the group consisting of ---- at first occurrence.

In claim 35, line 2, delete ---- 1-34---- and insert ----1, 2 or 4-34 -----.

Application/Control Number: 10/705,173

Art Unit: 1625

4. Claims 1, 2, 4-35 and 53, renumbered as claims 1-35, are allowed since the applicants have amended claims to delete non-elected subject matter as well as to

overcome all rejections.

5. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Charanjit S. Aulakh whose telephone number is

(571)272-0678. The examiner can normally be reached on Monday through Friday,

8:30 A.M. to 5:00 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thomas McKenzie can be reached on (571)272-0670. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Charanjit S. Aulakh Primary Examiner Page 3

Art Unit 1625